KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Research & Development (2016 - 2025)

Pfizer (PFE) has disclosed Research & Development for 17 consecutive years, with $3.2 billion as the latest value for Q4 2025.

  • Quarterly Research & Development changed N/A to $3.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $10.4 billion for FY2025, 3.56% down from the prior year.
  • Research & Development for Q4 2025 was $3.2 billion at Pfizer, up from $2.5 billion in the prior quarter.
  • The five-year high for Research & Development was $3.2 billion in Q4 2025, with the low at $2.0 billion in Q2 2021.
  • Average Research & Development over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2024.
  • The sharpest move saw Research & Development grew 25.73% in 2022, then fell 11.63% in 2025.
  • Over 5 years, Research & Development stood at $2.7 billion in 2021, then grew by 0.56% to $2.7 billion in 2022, then rose by 4.41% to $2.8 billion in 2023, then decreased by 7.71% to $2.6 billion in 2024, then grew by 23.4% to $3.2 billion in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $3.2 billion, $2.5 billion, and $2.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.